VANCOUVER, British Columbia, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that…
Scorpius subsidiary to manufacture novel biologic targeting substance use disorderDURHAM, N.C., Jan. 03, 2024 (GLOBE NEWSWIRE) -- NightHawk Biosciences (NYSE…
Additional Ewing Sarcoma Patient in Company’s Phase 1/2 Sarcoma Trial Achieves Partial Response; Objective Response Rate Among First-Relapse Ewing Patients…
CAMBRIDGE, Mass., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage RNA medicines company committed…
Pure Impact™ with PlyoPulse™ technology is a direct add-on Body module to the existing FDA cleared Sofwave medical aesthetic device…
CAMBRIDGE, Mass., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine…
ZUG, Switzerland and BOSTON, Jan. 03, 2024 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating…
SOUTH SAN FRANCISCO, Calif., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for…
AC Immune Progress Update on Phase 2 Active Immunotherapy Clinical Pipeline for Alzheimer's and Parkinson diseases ABATE Phase 1b/2 AD…
WESTON, Fla., Jan. 03, 2024 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA; “ZyVersa”), a clinical stage specialty biopharmaceutical company…